Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme

Less than 1 min.Read

By Investing Today

June 14, 2025

Facebook

Twitter

Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme

Attachment

2025 06 14 SBB EN

Hot this week

News Room

Inside information, negative profit warning – Oma Savings Bank Plc lowers its earnings guidance for 2025

June 15, 2025 0

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE, 15 JUNE...

News Room

Announcement regarding the governance of Renault Group

June 15, 2025 0

PRESS RELEASEJune 15, 2025 Announcement...

News Room

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

June 15, 2025 0

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic...

News Room

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

June 15, 2025 0

New late-breaking data at EAACI showed Dupixent outperformed Xolair...

News Room

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

June 15, 2025 0

With up to three years of follow-up, a single...

Topics

News Room

Inside information, negative profit warning – Oma Savings Bank Plc lowers its earnings guidance for 2025

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE, 15 JUNE...

News Room

Announcement regarding the governance of Renault Group

PRESS RELEASEJune 15, 2025 Announcement...

News Room

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic...

News Room

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair...

News Room

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

With up to three years of follow-up, a single...

News Room

Scatec signs PPA for 900MW onshore wind project in Egypt

Oslo/Cairo, 15 June 2025: Scatec ASA, a leading renewable...

News Room

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Oslo/Cairo, 15 June 2025: Scatec ASA has reached financial...

News Room

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

– Pharmacology modeling data presented at the European Academy...

Inside information, negative profit warning – Oma Savings Bank Plc lowers its earnings guidance for 2025

News Room June 15, 2025

Announcement regarding the governance of Renault Group

News Room June 15, 2025

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

News Room June 15, 2025

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

News Room June 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

News Room June 15, 2025

Popular Categories

News RoomFeatured CompaniesVideos

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme

Inside information, negative profit warning – Oma Savings Bank Plc lowers its earnings guidance for 2025

Announcement regarding the governance of Renault Group

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

Topics

Inside information, negative profit warning – Oma Savings Bank Plc lowers its earnings guidance for 2025

Announcement regarding the governance of Renault Group

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

Scatec signs PPA for 900MW onshore wind project in Egypt

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Related Articles

Inside information, negative profit warning – Oma Savings Bank Plc lowers its earnings guidance for 2025

Announcement regarding the governance of Renault Group

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

Company

Headlines

Inside information, negative profit warning – Oma Savings Bank Plc lowers its earnings guidance for 2025

Announcement regarding the governance of Renault Group

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

Newsletter